Simple Summary CA125 has been the most promising biomarker for screening ovarian
cancer; however, it still does not have an acceptable accuracy in population-based …

Ovarian cancer is the deadliest gynecological cancer, leading to over 152,000 deaths each
year. A late diagnosis is the primary factor causing a poor prognosis of ovarian cancer and …

Simple Summary Ovarian high-grade serous carcinoma (HGSC) has a 5-year survival rate
of less than 50%, making it one of the most lethal gynecological cancers for women in the …

The greatest unmet needs in biomarker discovery are those discoveries that lead to the
development of clinical diagnostic tests. These clinical diagnostic tests can provide early …

Medical diagnostics and treatment has advanced from a one size fits all science to treatment
of the patient as a unique individual. Currently, this is limited solely to genetic analysis …

Background Women with adnexal mass suspected of ovarian malignancy are likely to
benefit from consultation with a gynecologic oncologist, but imaging and biomarker tools to …

Ovarian cancer is a lethal gynecologic malignancy with greater than 70% of women
presenting with advanced stage disease. Despite new treatments, long term outcomes have …

Objectives To aid primary care physicians, emergency medicine physicians, and
gynaecologists in the initial investigation of adnexal masses, defined as lumps that appear …

Altered lipid metabolism has emerged as an important feature of ovarian cancer (OC), yet
the translational potential of lipid metabolites to aid in diagnosis and triage remains …

Objective Serous ovarian carcinoma (OC) represents a leading cause of cancer-related
death among US women. Non-invasive tools have recently emerged for discriminating …